NEW YORK, Dec. 07, 2022 (GLOBE NEWSWIRE) -- H1, the connecting force for global healthcare provider, clinical, science, and research information, today released its predictions for 2023 to help life sciences, pharmaceutical, and healthcare companies understand larger industry trends and dynamics to plan and prepare for the new year.

Access to medicine and healthcare is a basic human right. Access to the best healthcare information is also a basic human right – one that will be more important in the 21st century than ever before. When roughly one-third of all data around the world is generated within the healthcare industry, it’s clear that healthcare data holds massive potential to improve patient care. H1 is at the forefront of this movement to democratize healthcare information. Today, H1 maintains the industry’s leading ecosystem of global information, covering 10+ million HCPs, 10+ billion global claims, 250+ million patients, and 420+ thousand clinical trials across 800,000 facilities worldwide. As we approach 2023, H1 has tapped into its wealth of data and insights from working with the world’s top pharmaceutical and medical device companies to identify trends and deliver key predictions that will impact the future of data enablement, advancement of medicine and drug development, and health equity in the coming year.

“From new government directives around data to global events that impacted clinical trials, 2022 was another monumental year for the healthcare industry,” said Ariel Katz, CEO & co-founder of H1. “2023 will bring its own unique set of challenges and we’ll see the industry take profound steps to evolve through greater investment in data democratization, an emphasis on using real-world data, a renewed commitment to diversity, and most importantly, a focus on accessible and equitable healthcare.”

Katz’s top predictions for 2023 include:

Another H1 executive has also shared thoughts on what’s in store for 2023. In her role as Vice President of Client Solutions, Stacey Rivkin works closely with teams across the pharma and life sciences spectrum, including clinical operations and feasibility teams for trials, Medical Affairs teams, MSLs, and Key Opinion Leaders (KOLs).

“We’ve also learned that the roles of Medical Affairs and MSLs are evolving, as is the notion of what defines a modern KOL. This will be critical to improving health equity, patient access, and accelerating go-to-market activities,” Rivkin states.

Her top three predictions impacting these groups include:

To make strides in achieving health equity, the industry will need to prioritize making de-identified healthcare data accessible and shift how it defines and engages with important stakeholders. For more information on how H1 can help, visit h1.co.

About H1
H1 is the connecting force for global HCP, clinical, scientific and research information. The H1 Connect platform democratizes access to HCP knowledge and groundbreaking insights for life sciences, academic medical institutions, health systems, and payors. H1 Connect fuels a robust product suite that helps customers discover and engage industry experts, drive equitable research, access groundbreaking science, and accelerate commercial success with the most robust and accurate healthcare professional data. Learn more at h1.co.

Media Contact:
Anya Nelson
Scratch Marketing + Media for H1
anyan@scratchmm.com